Third time’s the charm: Fangzhou finally finds winning tonic for Hong Kong IPO
The company has become the latest internet healthcare stock to list, but continues to lose money and remains heavily reliant on drug sales Key Takeaways: Fangzhou has been approved to…
Slowing revenue growth hurts online drug platform YSB
The B2B drug distributor posted higher annual revenues and swung to an adjusted profit, but disappointed investors still sent the firm’s stock down 9% on the day after the earnings…
Ping An Health pins recovery hopes on new leadership
The ailing healthcare platform brought in a whole new management team three years ago to drive a business turnaround but it is changing leaders again Key Takeaways: The Covid pandemic…
FAST NEWS: Dingdang Health forecasts 70% narrowing of book loss
The latest: Digital retail pharmacy Dingdang Health Technology Group Ltd. (9886.HK) said Wednesday it expects its net loss for the first half of this year to narrow by more than…
Profits recover at Alibaba Health but prognosis unclear
The digital pharmacy and healthcare provider returned to profit in the last fiscal year but is still struggling to limit its reliance on drug sales Key Takeaways: Alibaba Health delivered…
Are Pharmacy Closures the Tonic Behind Deshengtang’s Profits?
The druggist, which has applied for a Hong Kong IPO, reported a tiny profit in the first nine months of last year, possibly due to savings after large-scale store closuresKey…
Catching Listing Chill, Dingdang Health Slashes Hong Kong IPO
China’s third largest digital retail pharmacy has been approved for a Hong Kong IPO, but cut the size by 90% from an earlier target Key Takeaways: Dingdang Health has passed…
Recent Articles
RELATED ARTICLES
-
BRIEF: Fangzhou adjusted profit jumps 139% on improving technology, efficiency
6086.HK -
Cash-hungry Mabwell seeks financial tonic from Hong Kong investors
688062.SHG
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Bumper dividend could trigger buyout for Ping An Health
1833.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
